Literature DB >> 11170624

Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.

R C Rizzo1, J Tirado-Rives, W L Jorgensen.   

Abstract

The interactions and energetics associated with the binding of 20 HEPT and 20 nevirapine nonnucleoside inhibitors of HIV-1 reverse transcriptase (RT) have been explored in an effort to establish simulation protocols and methods that can be used in the development of more effective anti-HIV drugs. Using crystallographic structures as starting points, all 40 inhibitors were modeled in the bound and unbound states via Monte Carlo (MC) statistical mechanics methods. Potentially useful descriptors of binding affinity were configurationally averaged for each inhibitor during the MC simulations, and correlations were sought with reported experimental activities. A viable regression equation was obtained using only four descriptors to correlate the 40 experimental activities with an r(2)() of 0.75 and cross-validated q(2)() of 0.69. The computed activities show a rmsd of 0.94 kcal/mol in comparison with experiment and an average unsigned error of 0.69 kcal/mol. The MC results reveal three physically reasonable parameters that control the binding affinities: (1) loss of hydrogen bonds with the inhibitor is unfavorable, (2) burial of hydrophobic surface area is favorable, and (3) a good geometrical fit without steric clashes is needed for the protein-inhibitor complex. It is gratifying that the corresponding descriptors are statistically the most important quantities for determining the anti-HIVRT activity for the 40 compounds. Representative examples are also given in which structural and thermodynamic information from the MC simulations is used to help understand binding differences for related compounds. A key pi-type hydrogen bond has been identified between secondary-amide nevirapine analogues and Tyr188A of HIVRT that explains their otherwise surprising activity and the ineffectiveness of nevirapine against the Y188C mutant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170624     DOI: 10.1021/jm000255n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Relative solvation free energies calculated using an ab initio QM/MM-based free energy perturbation method: dependence of results on simulation length.

Authors:  M Rami Reddy; Mark D Erion
Journal:  J Comput Aided Mol Des       Date:  2009-09-17       Impact factor: 3.686

2.  Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.

Authors:  Jinfeng Liu; Xiao He; John Z H Zhang
Journal:  J Mol Model       Date:  2014-09-20       Impact factor: 1.810

3.  Computational studies and drug design for HIV-1 reverse transcriptase inhibitors of 3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) analogs.

Authors:  Hai-Feng Chen; Bo-Tao Fan; Chen-Yang Zhao; Lan Xie; Chun-Hong Zhao; Ting Zhou; Kuo-Hsiung Lee; Graham Allaway
Journal:  J Comput Aided Mol Des       Date:  2005-04       Impact factor: 3.686

4.  Molecular dynamics simulation of S100B protein to explore ligand blockage of the interaction with p53 protein.

Authors:  Zhigang Zhou; Yumin Li
Journal:  J Comput Aided Mol Des       Date:  2009-07-14       Impact factor: 3.686

5.  Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations.

Authors:  Shi-Feng Chen; Yang Cao; Jiong-Jiong Chen; Jian-Zhong Chen
Journal:  J Mol Model       Date:  2013-10-02       Impact factor: 1.810

6.  Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Authors:  Barbara A Rath; Richard A Olshen; Jerry Halpern; Thomas C Merigan
Journal:  Viruses       Date:  2012-08-07       Impact factor: 5.048

7.  Theoretical investigation of the interactions in binding pocket of Reverse Transcriptase.

Authors:  Kamlesh Kumar Sahu; Nozomu Hatakeyama; Akira Miyamoto
Journal:  Saudi J Biol Sci       Date:  2014-12-31       Impact factor: 4.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.